Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism spectrum disorder and facioscapulohumeral muscular dystrophy programs. The company’s pipeline also includes programs for myotonic dystrophy and Huntington’s disease.